

1. Record Nr.	UNINA9910146099803321
Titolo	Tumor-associated antigens [[electronic resource] ] : identification, characterization, and clinical applications // edited by Olivier Gires and Barbara Seliger
Pubbl/distr/stampa	Weinheim, : Wiley-VCH, c2009
ISBN	1-282-02189-3 9786612021893 3-527-62597-6 3-527-62598-4
Descrizione fisica	1 online resource (386 p.)
Altri autori (Persone)	GiresOlivier SeligerBarbara
Disciplina	616.994079
Soggetti	Tumor antigens Tumors - Immunological aspects
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Tumor-Associated Antigens : Identification, Characterization, and Clinical Applications; Contents; List of Contributors; Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs; 1 T Cell Antigens in Cancer; 1.1 Introduction; 1.2 Generation of T-cell Epitopes; 1.2.1 Subclasses of Tumor-associated T-cell Antigens; 1.2.1.1 Unique Tumor Antigens; 1.2.1.2 Cancer Testis Antigens; 1.2.1.3 Differentiation Antigens; 1.2.1.4 Overexpressed Antigens; 1.3 Identification of T-cell Antigens and their Epitopes; 1.3.1 T-cell Antigens for Cancer Immunotherapy - How are Candidates Selected? 1.4 ConclusionsReferences; 2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines; 2.1 Introduction; 2.2 Tumor Antigen Classes; 2.2.1 Oncofetal Antigens; 2.2.2 Oncogenes as Tumor Antigens; 2.2.3 Overexpressed Normal Molecules as Tumor Antigens; 2.2.4 Cancer-Testis (CT) Antigens; 2.2.5 Minor Histocompatibility Antigens (mHAgs) as Tumor Antigens; 2.2.6 Human Melanoma Antigens; 2.2.7 Human Glioma Antigens and Immunosurveillance in the CNS; 2.2.8 Heat Shock Proteins, Efficient

## Carriers of Tumor Antigens

2.2.9 Dendritic Cells, Efficient Cross-presenters of Tumor Antigens

2.10 Spontaneous and Vaccine-induced Immunity and the Tumor

Microenvironment; 2.3 Summary; References; Part Two Methods to

Detect TAAs; 3 Humoral Immune Responses against Cancer Antigens:

Serological Identification Methods. Part I: SEREX; 3.1 Introduction; 3.2

The SEREX Approach; 3.2.1 Identification of Human Tumor Antigens by

SEREX; 3.2.2 Specificity of Human Tumor Antigens; 3.2.2.1 Shared

Tumor Antigens; 3.2.2.2 Differentiation Antigens; 3.2.2.3 Antigens

Encoded by Mutated Genes; 3.2.2.4 Viral Genes

3.2.2.5 Overexpressed Genes; 3.2.2.6 Amplified Genes; 3.2.2.7 Splice

Variants of Known Genes; 3.2.2.8 Cancer-related Autoantigens; 3.2.2.9

Non-cancer-related Autoantigens; 3.2.2.10 Products of

Underexpressed Genes; 3.2.3 Significance of Antibodies against SEREX

Antigens; 3.2.4 Reverse T Cell Immunology; 3.2.5 Functional

Significance of Human Tumor Antigens; 3.2.6 The Human Cancer

Immunome; 3.2.7 Perspectives for Vaccine Development; 3.3

Conclusions; References; 4 Humoral Immune Responses against Cancer

Antigens: Serological Identification Methods. Part II: Proteomex and

AMIDA; 4.1 Introduction

4.1.1 A Humoral Response against Self-antigens: The Notion of Tumor-

associated Antigens; 4.2 Implementation of Serum Antibodies:

Serological Screening Technologies; 4.2.1 PROTEOMEX, alias SERPA and

SPEARS; 4.2.1.1 PROTEOMEX Technology and its 'Pros' and 'Cons';

4.2.1.2 Candidate Biomarkers Identified by PROTEOMEX; 4.2.1.3

Implementation of Candidate Biomarkers in the Clinic; 4.2.2 AMIDA;

4.2.2.1 Autologous AMIDA; 4.2.2.2 Allo-AMIDA; 4.2.3 Advantages and

Disadvantages of AMIDA; 4.3 AMIDA Antigens and Clinical Application;

4.3.1 Diagnostic TAAs Detected with AMIDA Screening

4.3.2 Therapeutic Markers

---

### Sommario/riassunto

The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies. The result is a must-have for biologists and oncologists in science, clinics and industry.

---